Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
13.76(c) 13.57(c) 13.27(c) 13.25(c) 14.1 Last
196 854 206 192 108 413 206 847 133 429 Volume
-3.30% -1.38% -2.21% -0.15% +6.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 75,9 M - -
Net income 2021 -131 M - -
Net cash position 2021 127 M - -
P/E ratio 2021 -2,89x
Yield 2021 -
Sales 2022 45,6 M - -
Net income 2022 -194 M - -
Net cash position 2022 23,4 M - -
P/E ratio 2022 -2,58x
Yield 2022 -
Capitalization 404 M 404 M -
EV / Sales 2021 3,65x
EV / Sales 2022 8,35x
Nbr of Employees 137
Free-Float 94,9%
More Financials
Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential... 
More about the company
Ratings of Mirum Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about MIRUM PHARMACEUTICALS, INC.
12/06Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 202..
BU
11/30INSIDER BUY : Mirum Pharmaceuticals
MT
11/22Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
11/19MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statem..
AQ
11/18Longeveron Shares Soar 120% on Key FDA Designation
DJ
11/17Mirum to Sell Livmarli Priority Review Voucher for $110 Million
MT
11/17Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
BU
11/15MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/15MIRUM PHARMACEUTICALS : Reports Third Quarter 2021 Financial Results and Provides Business..
PU
11/15Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/15Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
BU
11/15Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Ev..
BU
11/15Mirum Pharmaceuticals, Inc. Announces That A New Analysis Comparing Pooled Livmarli? (M..
CI
11/08Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conferenc..
BU
11/01Mirum Pharmaceuticals to Present Maralixibat Data at Scientific Conference
MT
More news
News in other languages on MIRUM PHARMACEUTICALS, INC.
11/17Mirum vendra le coupon d'évaluation prioritaire de Livmarli pour 110 millions de dollar..
11/01Mirum Pharmaceuticals présentera des données sur le Maralixibat lors d'une conférence s..
09/29Mirum Pharmaceuticals obtient l'autorisation de la FDA pour la solution orale Livmarli ..
09/21Mirum s'associe à Takeda pour développer et commercialiser un candidat médicament contr..
07/27Mirum Pharmaceuticals accorde à GC Pharma les droits exclusifs de commercialisation d'u..
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MIRM | US6047491013 | MarketScreener
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 13,25 $
Average target price 54,71 $
Spread / Average Target 313%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.-19.24%404
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888